Dissecting Mechanisms of Ceftolozane Resistance in Pseudomonas aeruginosa: Insights from PK/PD Modeling

Study Background and Research Question

Multidrug-resistant (MDR) Pseudomonas aeruginosa poses a persistent threat in clinical settings, particularly due to its capacity to evade β-lactam antibiotics through diverse resistance mechanisms. Ceftolozane, a time-dependent oxyimino cephalosporin antibacterial, often paired with tazobactam, has been a valuable agent against MDR P. aeruginosa, especially strains resistant to carbapenems. Yet, clinical resistance to ceftolozane/tazobactam (C/T) is increasingly reported, often linked to mutations in chromosomal ampC (encoding a cephalosporinase) and its regulatory genes such as ampD. The primary research question addressed in the reference study is: How do specific mutations in ampC and ampD contribute to both acquired and adaptive resistance to ceftolozane/tazobactam, and can these effects be quantitatively modeled to inform future susceptibility testing and therapy strategies? (paper)

Key Innovation from the Reference Study

The central innovation lies in the application of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling to parse the distinct contributions of ampC and ampD mutations to resistance. Unlike traditional minimum inhibitory concentration (MIC) determinations, which are static and may not reveal time-dependent (adaptive) resistance phenomena, the modeling approach employed captures the full time-course of bacterial growth, killing, and the emergence of resistance under various antibiotic exposures (paper). This enables discrimination between initial resistance (present at treatment onset) and adaptive resistance that emerges during antibiotic exposure, providing a more nuanced understanding of evolutionary trajectories in the pathogen.

Methods and Experimental Design Insights

To interrogate the genetic and phenotypic basis of resistance development, the study generated precise single and double mutants in the PAO1 reference strain: PAO1-AmpC_G183D (ampC mutation), PAO1-AmpD_H157Y (ampD mutation), and the double mutant PAO1-AmpC_G183D/AmpD_H157Y. Additionally, clinical isolates were used to compare resistance phenotypes before and after mutation reversal. Sequential time-kill curve experiments were performed on all strains, capturing bacterial viability over time in the presence of C/T and imipenem (IMI). The resulting datasets were analyzed using a semi-mechanistic PK/PD model incorporating adaptation, which allowed precise quantification of both initial and evolving resistance.

Protocol Parameters

• in vitro antibacterial susceptibility assay | 0.03–32 mg/L ceftolozane | recommended for C/T-resistant and susceptible P. aeruginosa | enables detection of subtle shifts in susceptibility due to mutations | product_spec
• neutropenic mouse thigh infection model | typical inoculum 10⁶–10⁷ CFU/thigh | evaluation of in vivo bactericidal activity | allows PK/PD target validation under physiological conditions | workflow_recommendation
• PK/PD modeling | dynamic time-kill data, multiple sampling points | applicable to dissecting both initial and adaptive resistance | provides quantitative framework for resistance evolution | paper
• ceftolozane dosing regimen | 1 g q8h (cIAI/UTI), 2 g q8h (HAP/VAP, high clearance) | clinical translation of in vitro findings | ensures free drug concentrations above MIC for optimal intervals | product_spec

Core Findings and Why They Matter

Whole genome sequencing of isogenic clinical isolates revealed two key mutations: a G183D substitution in AmpC and an H157Y substitution in AmpD. Through genetic engineering and subsequent time-kill experiments, the following quantitative insights were obtained:

• Initial EC₅₀ values for ceftolozane increased by 1.4-, 4.1-, and 29-fold in the single ampC, single ampD, and double mutants, respectively, compared to wild-type PAO1 (paper).
• At experiment end, EC₅₀ increases were even more pronounced: 320-, 12.4-, and 55-fold for the same mutants, indicating substantial adaptive resistance.
• Double mutants consistently exhibited higher resistance than single mutants at all time points.
• Reversal of mutations in the resistant clinical background reduced EC₅₀ for C/T from 80.5 mg/L to 6.77 mg/L, confirming their direct role in resistance.
• Interestingly, while ampC and ampD mutations promoted resistance to ceftolozane, the ampC mutation alone restored susceptibility to imipenem, highlighting complex trade-offs in β-lactam resistance pathways.

These findings illustrate that resistance in P. aeruginosa is not static; adaptive mechanisms can substantially worsen the resistance phenotype during therapy. The modeling approach enables researchers to distinguish between resistance present at baseline and resistance that emerges under treatment pressure—an advance over conventional MIC-based workflows.

Comparison with Existing Internal Articles

Internal resources reinforce and extend the reference study’s mechanistic and translational insights:

• Dissecting Ceftolozane Resistance in P. aeruginosa via PK/PD Modeling—This article parallels the reference study by applying PK/PD modeling to ampC/ampD mutations, corroborating the quantitative and time-dependent aspects of resistance evolution.
• Ceftolozane Sulfate: Advancing Translational Strategies Against P. aeruginosa—Offers a broader view on leveraging ceftolozane sulfate in both in vitro and in vivo models, emphasizing protocol optimization and clinical translation. The current study’s findings on adaptive resistance strengthen the rationale for dynamic, rather than static, susceptibility testing in translational workflows.
• Ceftolozane Sulfate: Protocol Optimization for Antibacterial Assays—Provides practical guidance on in vitro susceptibility protocols using ceftolozane sulfate, which aligns with the reference study’s call for nuanced, time-resolved assessment of resistance phenotypes.

Limitations and Transferability

While the study’s semi-mechanistic PK/PD modeling offers a powerful tool for dissecting both acquired and adaptive resistance, some limitations remain. First, the work focuses on defined mutations in a reference and isogenic clinical strain background, which may not capture the full complexity of resistance mechanisms in diverse clinical isolates. Second, while time-kill and PK/PD modeling provide greater resolution than MIC alone, their implementation requires specialized expertise and resources not available in all microbiology laboratories. Third, the model’s predictions are most robust for β-lactam/β-lactamase inhibitor combinations and may need recalibration for other compound classes or combinatorial therapies. Nevertheless, the study’s approach is adaptable to other MDR pathogens where time-dependent resistance is suspected, provided similar genetic and experimental tools are available (paper).

Research Support Resources

To facilitate translational research on cephalosporin resistance mechanisms and pharmacodynamic modeling, researchers can utilize Ceftolozane sulfate (SKU C8753) from APExBIO for in vitro susceptibility testing and dynamic PK/PD studies. This reagent supports both static MIC assays and advanced, time-resolved models, as outlined in the reference study and related workflow recommendations (source: product_spec). For protocol refinements and troubleshooting, internal resources such as the protocol optimization guide (internal article) offer actionable insights. By integrating these tools and methodologies, research teams can better capture the dynamics of resistance emergence—informing both assay development and the translational pipeline for next-generation antibacterials.